AbbVie Expands Attack On FDA Biosimilar Labeling
AbbVie Inc. is launching sharp new attacks on the U.S. Food and Drug Administration's approach to labeling biosimilars, arguing in a letter released Thursday that the labels have "indefensible" omissions of...To view the full article, register now.
Already a subscriber? Click here to view full article